Leadership

Dan Passeri is a seasoned biotechnology executive with over 20 years of experience managing drug discovery and development programs as well as business development activities on behalf of publicly traded companies, with deep experience in both oncology and strategic partnership generation. Prior to joining Cue Biopharma, Mr. Passeri served as President and Chief Executive Officer as well as Vice Chairman of the Board of Curis, Inc. Prior to joining Curis, he was employed by GeneLogic Inc., most recently as Senior Vice President, Corporate Development and Strategic Planning. Prior to his work at GeneLogic, Mr. Passeri served as Director of Technology Management at Boehringer Mannheim. Mr. Passeri received a J.D. from the National Law Center at George Washington University, an M.Sc. in Biotechnology from the Imperial College of Science, Technology and Medicine at the University of London and a B.S. in Biology from Northeastern University.

Anish Suri is an immunologist with extensive experience in basic and translational research focused on immuno-oncology, autoimmune disorders, transplantation rejection, and inflammation. Prior to joining Cue Biopharma, he held roles of increasing responsibility at Janssen Pharmaceutical Companies, including a key leadership position overseeing strategic Immunoscience initiatives. Prior to Janssen, he was responsible for providing strategic guidance to immuno-oncology and immunology drug discovery programs at Bristol-Myers Squibb Pharmaceutical Research Institute. Prior to his work in the pharmaceutical industry, Dr. Suri was Assistant Professor of Pathology and Immunology at Washington University School of Medicine. He received his Ph.D. in immunology from Washington University in St Louis, Missouri.

Kenneth Pienta is a highly-respected leader in the understanding of cancer metastases and the role of the tumor microenvironment in cancer development and immunosuppression. Dr. Pienta is the Donald S. Coffey Professor of Urology, as well as a Professor of Oncology, Pharmacology and Molecular Sciences, and Chemical and Biomolecular Engineering at Johns Hopkins University. Currently, he is the Director of Research at the Brady Urological Institute and also serves as the co-Director of the Johns Hopkins Individualized Health Initiative (Hopkins inHealth) to better define the practice of precision medicine. He has been the principal investigator on numerous local and national clinical trials and has a proven track record in developing multi-disciplinary translational research programs, diagnostics, and therapeutics. Dr. Pienta is the author of more than 350 peer-reviewed articles, and is a two-time American Cancer Society Clinical Research Professor Award recipient. Dr. Pienta received a B.A. in human biology from Johns Hopkins University and an M.D. from the Johns Hopkins University School of Medicine, and is board certified in oncology.

Colin Sandercock brings more than 30 years of experience advising life sciences companies on a broad range of legal matters, including domestic and international patent litigation, compliance, procurement, and licensing. Before joining Cue Biopharma, Sandercock was most recently a Partner at Perkins Coie since 2009. Prior to Perkins Coie, he held positions within legal firms including Proskauer Rose where he co-chaired the firm’s Life Science Practice Group; Heller Ehrman, where he co-chaired the firm’s Intellectual Property Practice Group; and Foley & Lardner, where he chaired the firm’s Chemical Practice Group. His technical experience includes life science, pharmaceutical compositions and biologics, organic and inorganic chemistries, as well as chemical and biochemical engineering. Sandercock has served as an adjunct professor of law at George Washington University Law School, lecturing on the licensing of intellectual property rights, and on the AAA Patent Advisory Committee for Patent Disputes. He received his J.D. from the Catholic University of America and received a M.S.E. in Engineering degree in Chemical and Biochemical Engineering from the University of Pennsylvania, and a B.S. in Chemistry and Mathematics from Moravian College.

Kerri-Ann Millar serves as the Vice President of Finance and Principal Finance and Accounting Officer. Before joining Cue Biopharma, Ms. Millar served as Corporate Controller for Flexion Therapeutics, Inc., a biopharmaceutical company focused on the development of local therapies for the treatment of patients with osteoarthritis, where she developed the finance function for the newly public company to support the commercialization of its first approved drug. Prior to Flexion Therapeutics, she served as a Finance Specialist for Curis, Inc., a biotechnology company focused on the development of oncology treatments. Prior to Curis, Ms. Millar spent over 10 years in audit and finance functions at several investment banks in the Boston area and four years at PricewaterhouseCoopers. She earned a B.S. in Accounting and Finance from Boston University and is a Certified Public Accountant.